Picture of virus

Open Access research that helps to deliver "better medicines"...

Strathprints makes available scholarly Open Access content by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), a major research centre in Scotland and amongst the UK's top schools of pharmacy.

Research at SIPBS includes the "New medicines", "Better medicines" and "Better use of medicines" research groups. Together their research explores multidisciplinary approaches to improve understanding of fundamental bioscience and identify novel therapeutic targets with the aim of developing therapeutic interventions, investigation of the development and manufacture of drug substances and products, and harnessing Scotland's rich health informatics datasets to inform stratified medicine approaches and investigate the impact of public health interventions.

Explore Open Access research by SIPBS. Or explore all of Strathclyde's Open Access research...

Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths : a before (2006-10) versus after (2011-13) comparison

Bird, Sheila M. and McAuley, Andrew and Perry, Samantha and Hunter, Carole (2016) Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths : a before (2006-10) versus after (2011-13) comparison. Addiction. ISSN 0965-2140

[img]
Preview
Text (Bird-etal-Addiction2016-effectiveness-of-Scotland's-National-Naloxone-Programme-for-reducing-opioid-related-deaths)
Bird_etal_Addiction2016_effectiveness_of_Scotland_s_National_Naloxone_Programme_for_reducing_opioid_related_deaths.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (231kB) | Preview

Abstract

Aims: To assess the effectiveness for Scotland's National Naloxone Programme (NNP) bycomparison between 2006-10 (before) and 2011-13 (after NNP started in January2011) and to assess cost-effectiveness. Design: This was a pre-post evaluation of a national policy. Cost-effectiveness was assessedby prescription costs against life-years gained per opioid-related death (ORD) averted. Setting: Scotland, in community settings and all prisons. Intervention: Brief training and standardized naloxone supply became available to individuals at risk of opioid overdose. Measurements: ORDs as identified by National Records of Scotland. Look-back determined the proportion of ORDs who, in the 4 weeks before ORD, had been (i) released from prison (primary outcome) and (ii) released from prison or discharged from hospital (secondary). We report 95% confidence intervals for effectiveness inreducing the primary (and secondary) outcome in 2011-13 versus 2006-10. Prescription costs were assessed against 1 or 10 life-years gained per averted ORD. Findings: In 2006-10, 9.8% of ORDs (193 of 1970) were in people released from prison within 4 weeks of death, whereas only 6.3% of ORDs in 2011-13 followed prison release(76 of 1212, P < 0.001; this represented a difference of 3.5% [95% confidence interval (CI) = 1.6-5.4%)]. This reduction in the proportion of prison release ORDs translates into 42 fewer prison release ORDs (95% CI =19-65) during 2011-13, when 12 000 naloxone kits were issued at current prescription cost of £225 000. Scotland's secondary outcome reduced from 19.0 to 14.9%, a difference of 4.1% (95% CI = 1.4-6.7%). Conclusions: Scotland's National Naloxone Programme, which started in 2011, was associated with a 36% reduction in the proportion of opioid-related deaths that occurred in the 4 weeks following release from prison.